Mumbai to get high-tech cancer hospital for women and children

Google+ Pinterest LinkedIn Tumblr +

plasma waves close upCancer treatment for women and children is set to take a big leap in about two and a half years, with Mumbai getting a world-class hospital.

The facility, which will come up at Parel, will be the first hospital in the country to offer proton beam therapy.

HLL Lifecare Ltd. (HLL), a public sector undertaking under the Ministry of Health and Family Welfare, has teamed up with the Tata Memorial Centre (TMC) to construct the hospital at an estimated cost of Rs350 crore.

The parties on Wednesday signed a memorandum of understanding to appoint HLL’s infrastructure development division as the project management consultant. The hospital is expected to begin operation in early 2017.

The HLL-TMC project will include a hadron beam facility – the first of its kind in India and only the 12th in the world – to offer advanced and high-precision proton therapy. With the use of hadrons, a cancerous tumour can be irradiated with lesser damage to surrounding healthy tissues as compared to X-rays used in conventional radiation therapy.

“HLL is proud to be associated with Tata Memorial Centre in constructing India’s first national hadron beam facility and a cancer centre for women and children,” said Dr M Ayyappan, CMD of HLL, a mini-Ratna PSU based in Thiruvananthapuram. “Cancer patients can look forward to the most modern treatment once the hospital is operational”.

Commissioned in 1941, Tata Memorial Centre has acquired the reputation of being country’s most comprehensive centre for the prevention, treatment, education and research in cancer. It sees nearly 43,000 new patients a year from India and neighbouring nations. Over 1,000 patients visit its outpatient department every day.

Source: DNA India

Share.

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Comments are closed.